The Relative Strength (RS) Rating for Phreesia moved up into a new percentile Monday, as it got a lift from 68 to 79.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's unique RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks compares to other publicly traded companies.
Decades of market research shows that the best stocks typically have an RS Rating north of 80 in the early stages of their moves. See if Phreesia can continue to show renewed price strength and hit that benchmark.
Phreesia is working on a consolidation with a 30.53 entry. See if the stock can break out in heavy trade.
The company posted 0% earnings growth last quarter, while sales growth came in at 15%.
The company earns the No. 7 rank among its peers in the Computer Software-Medical industry group. Doximity, Waystar Holding and Veeva Systems Cl A are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
